Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology · BRCA Gene Mutation

Do I Meet the NCCN Criteria for BRCA Genetic Testing?

At a Glance

The NCCN recommends BRCA genetic testing if you or a close relative have certain red flags. These include breast cancer diagnosed at age 50 or younger, triple-negative breast cancer, male breast cancer, ovarian or pancreatic cancer, high-risk prostate cancer, or Ashkenazi Jewish ancestry.

The National Comprehensive Cancer Network (NCCN) provides established guidelines to help doctors identify who is most likely to carry a pathogenic variant (a harmful mutation) in genes like BRCA1 and BRCA2. If your personal or family history includes certain “red flags,” medical guidelines strongly recommend genetic testing [1]. The standard NCCN red flags include a diagnosis of breast cancer at age 50 or younger, triple-negative breast cancer at any age, male breast cancer, any ovarian or pancreatic cancer, high-risk prostate cancer, or having Ashkenazi Jewish ancestry [1].

Understanding these criteria can help you advocate for yourself or your family members. Meeting just one of these red flags means you should be offered a referral to a genetic counselor, who can arrange for a simple blood or saliva test.

Breast Cancer Red Flags

Not everyone who gets breast cancer needs a BRCA test, but specific details about the diagnosis—whether in yourself or a close blood relative (such as a parent, sibling, child, grandparent, aunt, or uncle)—are strong indicators for testing:

  • Breast cancer at age 50 or younger: A breast cancer diagnosis at a younger age (50 or younger) is a major red flag [2]. Genetic mutations are much more common in early-onset cancers, and knowing your status can change which surgeries or treatments your care team recommends [3].
  • Triple-negative breast cancer (TNBC): This is a specific type of breast cancer that does not have estrogen, progesterone, or HER2 receptors. Guidelines recommend testing for individuals with TNBC, as this subtype is strongly linked to BRCA mutations [4]. Identifying a mutation in TNBC can open up targeted treatment options [5].
  • Male breast cancer: Breast cancer in men is rare and is considered a high-risk indicator for a BRCA2 mutation [6]. Guidelines recommend universal genetic testing for any man diagnosed with breast cancer [7].

Other Cancer Types

BRCA mutations are most famous for their link to breast cancer, but they are also responsible for driving other specific cancers. If you or a close blood relative have had any of the following, you meet the criteria for testing:

  • Ovarian cancer: Any diagnosis of invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer automatically qualifies a person for BRCA testing, regardless of their age or family history [8]. About 15% to 20% of these cases are driven by germline BRCA mutations, and testing is critical for determining the best maintenance therapies [9].
  • Pancreatic cancer: Universal testing is now recommended for anyone diagnosed with pancreatic cancer (specifically pancreatic ductal adenocarcinoma) [10]. A significant number of people with pancreatic cancer carry actionable genetic mutations, even if they have no family history of the disease [11].
  • Prostate cancer: High-risk, very-high-risk, regional, or metastatic prostate cancer is a major trigger for genetic testing [12]. Finding a BRCA mutation in advanced prostate cancer directly influences the use of targeted treatments like PARP inhibitors [13].

Cumulative Family History

Even if no single person in your family had cancer early enough or of a specific type to meet the criteria above, a pattern of cancers can still be a red flag. If multiple close blood relatives on the same side of your family (for instance, your mother and your maternal aunt) had breast or prostate cancer, the cumulative history often warrants a referral for genetic evaluation [1].

Ashkenazi Jewish Ancestry

People of Ashkenazi (Eastern European) Jewish descent have a much higher rate of carrying three specific BRCA “founder mutations” than the general population [14]. Because of this increased risk, recent guidelines state that testing for these specific mutations can be offered to anyone with Ashkenazi Jewish ancestry, even without a known family history of cancer [15]. If there is a personal or family history of breast, ovarian, pancreatic, or prostate cancer, comprehensive testing is strongly recommended [16].

Why These Red Flags Matter

If you meet any of these criteria, getting a genetic test is not just about knowing your future risk—it is a medically actionable step.

  • For your own treatment: If you currently have cancer, discovering a BRCA mutation can make you eligible for targeted therapies like PARP inhibitors (drugs that specifically target the way cancer cells repair their DNA) [17]. It can also guide surgical choices, such as whether to choose a lumpectomy or a bilateral mastectomy (removal of both breasts) [3].
  • For your family: If you test positive for a mutation, your blood relatives can undergo cascade testing (targeted testing for the exact mutation found in your family). This allows your relatives to take preventative measures before cancer ever develops [18].

Tip: Before your next doctor’s appointment, take some time to map out your family cancer history—including the exact cancer types and the approximate ages when your relatives were diagnosed. This is the exact information your doctor or genetic counselor will need.

Common questions in this guide

Do I meet the NCCN criteria for BRCA genetic testing?
You may meet the criteria if you or a close blood relative have had breast cancer at age 50 or younger, triple-negative breast cancer, male breast cancer, or any ovarian or pancreatic cancer. Ashkenazi Jewish ancestry and a cumulative family history of cancer are also major red flags.
Can BRCA genetic test results change my cancer treatment?
Yes, discovering a BRCA mutation can make you eligible for targeted therapies like PARP inhibitors, which target the way cancer cells repair their DNA. It can also help guide surgical decisions, such as choosing between a lumpectomy or a bilateral mastectomy.
Does having Ashkenazi Jewish ancestry mean I need a BRCA test?
People of Ashkenazi Jewish descent have a much higher rate of carrying specific BRCA founder mutations than the general population. Due to this increased risk, guidelines state that testing can be offered to anyone with this ancestry, even without a known family history of cancer.
What should I prepare before talking to my doctor about genetic testing?
Before your appointment, take time to map out your family cancer history. You should note which close blood relatives had cancer, the exact types of cancer they were diagnosed with, and their approximate ages at the time they were first diagnosed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I meet the NCCN criteria for BRCA genetic testing based on my personal and family history?
  2. 2.If I qualify, how do I get a referral to a licensed genetic counselor, and does insurance typically cover it?
  3. 3.Could the results of a genetic test change my current treatment plan or surgical options?
  4. 4.Given my family's history of cancer, should I be tested using a multi-gene panel rather than just looking at BRCA1 and BRCA2?
  5. 5.How does my specific family history or ancestry (such as Ashkenazi Jewish descent) influence which genetic tests I need?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    [Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].

    Foretová L, Macháčková E, Palácová M, et al.

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2016; (29 Suppl 1()):S9-13 doi:10.14735/amko2016s9.

    PMID: 26691937
  2. 2

    Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study.

    Rashid MU, Muhammad N, Naeemi H, et al.

    Hereditary cancer in clinical practice 2019; (17()):27 doi:10.1186/s13053-019-0125-5.

    PMID: 31528241
  3. 3

    Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis.

    Yadav S, Reeves A, Campian S, et al.

    Hereditary cancer in clinical practice 2017; (15()):11 doi:10.1186/s13053-017-0071-z.

    PMID: 28770017
  4. 4

    Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer.

    Emborgo TS, Saporito D, Muse KI, et al.

    JNCI cancer spectrum 2020; (4(2)):pkaa002 doi:10.1093/jncics/pkaa002.

    PMID: 32211581
  5. 5

    Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

    Tutt A, Tovey H, Cheang MCU, et al.

    Nature medicine 2018; (24(5)):628-637 doi:10.1038/s41591-018-0009-7.

    PMID: 29713086
  6. 6

    Five Italian Families with Two Mutations in BRCA Genes.

    Vietri MT, Caliendo G, D'Elia G, et al.

    Genes 2020; (11(12)) doi:10.3390/genes11121451.

    PMID: 33287145
  7. 7

    A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis.

    Yamada J, Fukuda K, Sugawara T, et al.

    International cancer conference journal 2024; (13(2)):139-143 doi:10.1007/s13691-023-00652-4.

    PMID: 38524651
  8. 8

    Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

    Tewari KS, Eskander RN, Monk BJ

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015; (21(17)):3829-35 doi:10.1158/1078-0432.CCR-15-0088.

    PMID: 26169965
  9. 9

    PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.

    Ledermann JA, El-Khouly F

    British journal of cancer 2015; (113 Suppl 1()):S10-6 doi:10.1038/bjc.2015.395.

    PMID: 26669450
  10. 10

    Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey.

    Grewal US, Patel RR, Loeffler BT, et al.

    Cancer 2026; (132(10)):e70446 doi:10.1002/cncr.70446.

    PMID: 42118569
  11. 11

    Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma.

    Fountzilas E, Eliades A, Koliou GA, et al.

    Cancers 2021; (13(2)) doi:10.3390/cancers13020198.

    PMID: 33429865
  12. 12

    Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

    Yadav S, Hart SN, Hu C, et al.

    JCO precision oncology 2019; (3()) doi:10.1200/PO.19.00067.

    PMID: 32923857
  13. 13

    New Therapeutic Options for BRCA Mutant Patients.

    Ghanem A, Domchek SM

    Annual review of medicine 2025; (76(1)):175-187 doi:10.1146/annurev-med-082523-083843.

    PMID: 39630850
  14. 14

    A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.

    Best AF, Tucker MA, Frone MN, et al.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019; (28(2)):293-302 doi:10.1158/1055-9965.EPI-18-0584.

    PMID: 30692095
  15. 15

    NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

    Daly MB, Pilarski R, Yurgelun MB, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(4)):380-391.

    PMID: 32259785
  16. 16

    Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.

    Tennen RI, Laskey SB, Koelsch BL, et al.

    Scientific reports 2020; (10(1)):7669 doi:10.1038/s41598-020-63466-x.

    PMID: 32376921
  17. 17

    BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.

    Wong W, Raufi AG, Safyan RA, et al.

    Cancer management and research 2020; (12()):2731-2742 doi:10.2147/CMAR.S211151.

    PMID: 32368150
  18. 18

    Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.

    Ahsan MD, Chandler IR, Min S, et al.

    Clinical obstetrics and gynecology 2024; (67(4)):702-710 doi:10.1097/GRF.0000000000000895.

    PMID: 39431491

This page explains NCCN guidelines for BRCA testing for educational purposes. Always consult your oncologist or a licensed genetic counselor to evaluate your specific family history and testing needs.

Get notified when new evidence is published on Hereditary breast and/or ovarian cancer syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.